Provectus on SPi NewsFollow our SPi News RSS Feed for provectus

Featured provectus News

[09 May 2019] Provectus Appoints Bruce Horowitz as Chief Operating Officer

[17 Apr 2019] Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

[25 Mar 2019] Provectus Appoints Heather Raines, CPA as Chief Financial Officer

[21 Mar 2019] Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10

[12 Feb 2019] PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA

[06 Dec 2018] PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10

[14 Nov 2018] PROVECTUS BIOPHARMACEUTICALS PROVIDES DRUG DEVELOPMENT UPDATE FOR IMMUNO-DERMATOLOGY ASSET PH-10

[12 Nov 2018] University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur

[25 Oct 2018] PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS

[24 Oct 2018] PROVECTUS ANNOUNCES PRESENTATION OF DATA FROM METASTATIC UVEAL MELANOMA COHORT OF PHASE 1 STUDY OF PV-10 IN LIVER CANCERS AT SMR 2018 CONGRESS

[23 Oct 2018] PROVECTUS ANNOUNCES PRESENTATION OF PHASE 1 TRIAL OF PV-10 FOR TREATMENT OF SYMPTOMATIC NEUROENDOCRINE TUMORS METASTATIC TO LIVER AT ESMO 2018 CONGRESS

[18 Sep 2018] PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG

[11 Sep 2018] PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS

[31 Jul 2018] PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10

[24 Jul 2018] PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT ESMO 2018 CONGRESS

[10 Jul 2018] PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING

[19 Jun 2018] PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE

[17 May 2018] PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

[07 May 2018] PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA

[25 Apr 2018] PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

[24 Apr 2018] PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS

[18 Apr 2018] PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY

[22 Feb 2018] PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10

[14 Dec 2017] PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE

[12 Dec 2017] PROVECTUS Announces resolutIon of SEC investigation

[18 Oct 2017] PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA

[10 Nov 2016] Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results

[30 Aug 2016] Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

[24 Mar 2016] Provectus Biopharmaceuticals to Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 at 4 pm (EDT)

[10 Feb 2016] Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST

[16 Dec 2015] Provectus Biopharmaceuticals, Inc. to Present at Biotech Showcase™ 2016 on Wednesday January 13, 2016 at 3:30 PM Pacific Time

[05 Nov 2015] Provectus Biopharmaceuticals Reports Third Quarter 2015 Financial Results

[20 Oct 2015] Provectus Biopharmaceuticals Will Hold Its 2015 Third Quarter Business Update Conference Call on Thursday, November 5, 2015, at 5 PM Eastern Standard Time

[06 Aug 2015] Provectus Biopharmaceuticals Reports Second Quarter 2015 Financial Results

[22 Jul 2015] Provectus Biopharmaceuticals Will Hold Its 2015 Second Quarter Business Update Conference Call on Thursday, August 6, 2015, at 4 PM Eastern Daylight Time

[24 Jun 2015] Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

[18 Jun 2015] Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

[06 Nov 2014] Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time

[26 Jul 2014] PROVECTUS 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Provectus Biopharmaceuticals, Inc. - PVCT

[22 Jul 2014] SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Provectus Biopharmaceuticals, Inc. to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- PVCT

[13 Jul 2014] SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Provectus Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- PVCT

[04 Jul 2014] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess Of $100,000 Investing in Provectus Biopharmaceuticals, Inc. to Contact the Firm -- PVCT

[01 Jul 2014] EQUITY ALERT: The Rosen Law Firm Reminds Provectus Biopharmaceuticals, Inc. Investors of Important Class Action Deadline - PVCT

[27 Jun 2014] SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT

[14 Jun 2014] Lifshitz & Miller Law Firm Announces Investigation of Annie's, Inc., Montage Technology Group Limited, OpenTable, Inc., Provectus Biopharmaceuticals, Inc., and The Bancorp Inc.

[14 Jun 2014] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Provectus Biopharmaceuticals, Inc. To Contact The Firm

[14 Jun 2014] SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Provectus Biopharmaceuticals, Inc. to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- PVCT

[13 Jun 2014] EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Fraud Class Action Against Provectus Biopharmaceuticals, Inc. -- PVCT

[13 Jun 2014] SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Provectus Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- PVCT


Still looking?

Type in your search term below and click Enter

World News from SPi

Sector Publishing Intelligence [SPi'] publishes financial news from around the world FAST. For breaking news announcements from companies, blogs and commentators, SPi provides up to the minute, integrated news on all aspects of financial markets and financial services.

SPi's extensive database of corporate information shows company details alongside breaking corporate news from the world’s largest news providers.

Publish Your Stories with SPI

Please click here to find out how to submit press releases and articles for publication.

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us